PMID

Data

Article Title

Organization

Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: an approach for inhibiting protein-protein interactions.

Sunesis Pharmaceuticals

Fragment-based drug discovery.

Sunesis Pharmaceuticals

Structure-activity relationship (SAR) of thea-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists.

Sunesis Pharmaceuticals

Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists.

Sunesis Pharmaceuticals

2-Aminobenzimidazoles as potent Aurora kinase inhibitors.

Sunesis Pharmaceuticals

A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties.

Sunesis Pharmaceuticals

Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio.

Sunesis Pharmaceuticals

Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry.

Sunesis Pharmaceuticals

Tethering identifies fragment that yields potent inhibitors of human caspase-1.

Sunesis Pharmaceuticals

4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139

Takeda Pharmaceutical

Insulin sensitisers and methods of treatment

Naia Metabolic

Compounds

Elanco Tiergesundheit

Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.

Universit�� Lille Nord De France

Design, synthesis, and anticonvulsant activity of some derivatives of xanthone with aminoalkanol moieties.

Jagiellonian University Medical College

HIV protease inhibitors

Merck Canada

Methods of treating retroviral infections and related dosage regimes

Chimerix

The complex of a bivalent derivative of galanthamine with torpedo acetylcholinesterase displays drastic deformation of the active-site gorge: implications for structure-based drug design.

Weizmann Institute of Science

A new series of potent oxindole inhibitors of CDK2.

Hoffmann-La Roche